Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg (equivalent: salmeterol, qty 0.05 mg); fluticasone propionate, quantity: 0.5 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: ?patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids ?patients who are symptomatic on current inhaled corticosteroid therapy,for the symptomatic treatment of patients with severe copd (fev1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone salmeterol ciphaler 500/50 is not indicated for the initiation of bronchodilator therapy in copd.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - formoterol fumarate 0.42%{relative} ((micronised)) - powder for inhalation - 12 mcg - active: formoterol fumarate 0.42%{relative} ((micronised)) excipient: lactose monohydrate

United States - English - NLM (National Library of Medicine)

ohm pharma inc. - cholesterol (unii: 97c5t2uq7j) (cholesterol - unii:97c5t2uq7j), bos taurus bile (unii: et3651zlou) (bos taurus bile - unii:et3651zlou), malmea depressa bark (unii: xa09475c3b) (malmea depressa bark - unii:xa09475c3b) - cholesterol 13 [hp_c] in 59 ml - uses: temporarily relieves ailments related with slow hepatic metabolism resulting in elevated cholesterol levels.** **this statement has not been evaluated by the fda. it is based on documented homeopathic materia medica .

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - formoterol fumatrate dihydrate - powder for inhalation - 6 microgram - selective beta-2-adrenoreceptor agonists

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - formoterol fumatrate dihydrate - powder for inhalation - 12 microgram - selective beta-2-adrenoreceptor agonists

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient. for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 100 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/500 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/250 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.